To include your compound in the COVID-19 Resource Center, submit it here.

ABT-450 plus ritonavir/ABT-267/ABT-333: Phase III data

The open-label, international Phase III PEARL-II (Study M13-389) trial in 179 treatment-experienced patients with chronic HCV genotype 1b infection and no evidence of liver cirrhosis showed that AbbVie's all-oral 3D regimen - comprising co-administration with once-daily 150 mg ABT-450 plus 100 mg

Read the full 429 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers